JPIAMR: Network proposal call; BARDA: DRIVe Accelerator call

Dear All: I trust you are now home after ECCMID in Madrid … it was an excellent meeting. Two new funding opportunities have recently crossed my radar: brief summaries and one key link for each are here with some further details below my signature. 

  • EU JPIAMR funding call: As part of its Virtual Research Institute (VRI) initiative, JPIAMR wants to fund as many as 22 collaborative research networks.
  • US BARDA Funding Opportunity Announcement: Building on the job opportunities recently announced for its DRIVe initiative, BARDA is creating an accelerator network providing technical and business development support services to programs funded by DRIVe.

This is great to see happening! All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/

JPIAMR call for network proposals: https://www.jpiamr.eu/pre-announcement-8th-call-building-the-foundation-of-the-jpiamr-vri/

  • JPIAMR seeks to encourage research alignment via establishing a Virtual Research Institute in AMR – a global network connecting research performing organisations, including institutes, centres, and infrastructures.
  • In partnership with ten member countries; Canada, Egypt, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, and the United Kingdom, JPIAMR is launching the 8th joint call for transnational Networks. The total budget of the call is approximately 1.1 million Euro. This Network Call “Building the Foundation of the JPIAMR Virtual Research Institute” aims to identify research community needs and develop ideas to form the foundation for the JPIAMR-VRI
  • Up to 22 Networks will be funded with up to €50 000 each coordinator to connect experts from research performing organisations and establish expertise clusters in the AMR community.
  • The formation of larger, multi-coordinator Networks is possible according to national rules.
  • Deadline for proposals is 4 July 2018.

BARDA DRIVEe Accelerator Network: Funding Opportunity Announcement: https://www.grants.gov/web/grants/view-opportunity.html?oppId=303785

  • BARDA’s newest Division of Research, Innovation and Ventures (DRIVe), will stimulate public-private partnership collaborations that spur innovation and investment in health security products and technologies to repopulate the development pipeline and stimulate the public good of the nation. 
  • A key component of this is the DRIVe Accelerator Network, where accelerators work together to identify promising, innovation and then provide wraparound technical and business development support services to programs funded by DRIVe. 
  • DRIVe Accelerator Network support teams will bring together a network of multiple accelerators, building on their individual strengths and unleash them to work directly with product developers funded by DRIVe.  
  • Product development candidates that graduate from DRIVe with support of the DRIVe Accelerator Network will be better positioned for advanced R&D investment, clinical development, and commercialization. 
  • The deadline for proposals is 17 May 2018.

Upcoming meetings of interest to the AMR community:

Share

Conflict-Borne XDR Superbugs: It’s Time for the PASTEUR Act!

Dear All: The recent publication of an exceptionally good plain-language summary of the AMR problem in Rolling Stone (yes, you read that correctly!) prompts today’s 3-part journey into the way(s) that war contributes to the threat of resistant superbugs. We’ve summarized the story in outline form — please explore the references for further details. And

ENABLE-2 funding now includes Hit Identification & Validation

23 July 2024 addenda x 2:  Mark Blaskovich let me know that the CO-ADD project is still offering a free in vitro screening service. See https://www.co-add.org/ to submit compounds for free testing vs 5 bacteria and 2 fungi; see https://db.co-add.org/ for structures and screening data on >100K compounds. The GHIT Fund has announced its 21st Request for Proposals for its Hit-to-Lead Platform to

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

Scroll to Top